Susan Schumer

2.2k total citations
17 papers, 1.2k citations indexed

About

Susan Schumer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Susan Schumer has authored 17 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Susan Schumer's work include Cancer Treatment and Pharmacology (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Childhood Cancer Survivors' Quality of Life (2 papers). Susan Schumer is often cited by papers focused on Cancer Treatment and Pharmacology (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Childhood Cancer Survivors' Quality of Life (2 papers). Susan Schumer collaborates with scholars based in United States, Denmark and Italy. Susan Schumer's co-authors include Stephen A. Cannistra, Balázs Halmos, Daniel B. Costa, Mark S. Huberman, Daniel G. Tenen, Susumu Kobayashi, Titus J. Boggon, Alexi A. Wright, Carolyn Krasner and Ursula A. Matulonis and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Susan Schumer

16 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Susan Schumer United States 9 517 425 422 338 177 17 1.2k
Pierre‐Alexandre Just France 17 415 0.8× 308 0.7× 269 0.6× 281 0.8× 265 1.5× 45 1.1k
J. J. Kavanagh United States 17 308 0.6× 545 1.3× 396 0.9× 181 0.5× 232 1.3× 50 1.2k
Melanie Mackean United Kingdom 20 563 1.1× 444 1.0× 873 2.1× 469 1.4× 167 0.9× 48 1.7k
C. Sessa Switzerland 13 267 0.5× 427 1.0× 651 1.5× 304 0.9× 141 0.8× 24 1.1k
Mariagrazia Distefano Italy 18 285 0.6× 273 0.6× 469 1.1× 195 0.6× 404 2.3× 38 1.2k
Kaoru Niimi Japan 20 478 0.9× 371 0.9× 338 0.8× 524 1.6× 273 1.5× 101 1.7k
Gianni Amunni Italy 20 261 0.5× 449 1.1× 358 0.8× 224 0.7× 526 3.0× 55 1.2k
Jurjees Hasan United Kingdom 15 326 0.6× 205 0.5× 371 0.9× 197 0.6× 70 0.4× 53 919
F. Raja United Kingdom 6 290 0.6× 781 1.8× 497 1.2× 112 0.3× 207 1.2× 12 1.2k
J. Carmichael United Kingdom 16 299 0.6× 374 0.9× 635 1.5× 134 0.4× 97 0.5× 24 987

Countries citing papers authored by Susan Schumer

Since Specialization
Citations

This map shows the geographic impact of Susan Schumer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Schumer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Schumer more than expected).

Fields of papers citing papers by Susan Schumer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Schumer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Schumer. The network helps show where Susan Schumer may publish in the future.

Co-authorship network of co-authors of Susan Schumer

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Schumer. A scholar is included among the top collaborators of Susan Schumer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Schumer. Susan Schumer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Mayer, Erica L., Dario Trapani, Se Eun Kim, et al.. (2025). The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer.. Journal of Clinical Oncology. 43(16_suppl). 517–517.
2.
Hirko, Kelly A., Faina Nakhlis, Jennifer R. Bellon, et al.. (2024). Abstract PO1-09-10: County-level Social Vulnerability and Survival among Women with Inflammatory Breast Cancer. Cancer Research. 84(9_Supplement). PO1–9. 1 indexed citations
3.
Liu, Joyce F., Niya Xiong, Susana M. Campos, et al.. (2021). Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. Journal of Clinical Oncology. 39(14). 1531–1539. 115 indexed citations
4.
Xiong, Niya, Hanneke Poort, Susan Schumer, et al.. (2021). Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecologic Oncology. 161(2). 581–586. 9 indexed citations
5.
Xiong, Niya, Nabihah Tayob, Carolyn Krasner, et al.. (2020). LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer. Annals of Oncology. 31. S1165–S1165. 11 indexed citations
6.
Tayob, Nabihah, Susana M. Campos, Alexi A. Wright, et al.. (2020). A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma. Gynecologic Oncology. 159. 5–5. 3 indexed citations
7.
8.
Liu, Joyce F., Niya Xiong, Susana M. Campos, et al.. (2020). A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma.. Journal of Clinical Oncology. 38(15_suppl). 6009–6009. 8 indexed citations
9.
Konstantinopoulos, Panagiotis A., Carolyn Krasner, Mary K. Buss, et al.. (2018). Phase II, two-stage study of avelumab in patients with microsatellite stable (MSS), microsatellite instable (MSI) and polymerase epsilon (POLE) mutated recurrent or persistent endometrial cancer. Gynecologic Oncology. 149. 24–25. 5 indexed citations
10.
Konstantinopoulos, Panagiotis A., Joyce F. Liu, William T. Barry, et al.. (2017). Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and POLE-mutated recurrent or persistent endometrial cancer.. Journal of Clinical Oncology. 35(15_suppl). TPS5615–TPS5615. 6 indexed citations
11.
Mayer, Erica L., Ann H. Partridge, Lyndsay N. Harris, et al.. (2009). Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Research and Treatment. 117(3). 615–623. 45 indexed citations
12.
Pories, Susan, David Zurakowski, Roopali Roy, et al.. (2008). Urinary Metalloproteinases: Noninvasive Biomarkers for Breast Cancer Risk Assessment. Cancer Epidemiology Biomarkers & Prevention. 17(5). 1034–1042. 77 indexed citations
13.
Costa, Daniel B., Balázs Halmos, Susan Schumer, et al.. (2007). BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations. PLoS Medicine. 4(10). e315–e315. 408 indexed citations
14.
Lam, Prudence, Stuart M. Berman, Robert L. Thurer, et al.. (2006). Phase II Trial of Sequential Chemotherapy Followed by Chemoradiation, Surgery, and Postoperative Chemotherapy for the Treatment of Stage IIIA/IIIB Non-Small-Cell Lung Cancer. Clinical Lung Cancer. 8(2). 122–129. 2 indexed citations
15.
Mayer, Erica L., Lyndsay N. Harris, Ann H. Partridge, et al.. (2006). Combination therapy with gefitinib and capecitabine in metastatic breast cancer (MBC): A phase I trial. Journal of Clinical Oncology. 24(18_suppl). 10564–10564. 1 indexed citations
16.
Burstein, Harold J., Leroy M. Parker, Aparna Keshaviah, et al.. (2005). Efficacy of Pegfilgrastim and Darbepoetin Alfa As Hematopoietic Support for Dose-Dense Every-2-Week Adjuvant Breast Cancer Chemotherapy. Journal of Clinical Oncology. 23(33). 8340–8347. 43 indexed citations
17.
Schumer, Susan & Stephen A. Cannistra. (2003). Granulosa Cell Tumor of the Ovary. Journal of Clinical Oncology. 21(6). 1180–1189. 447 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pierre‐Alexandre Just Breakdown of academic impact, for papers by J. J. Kavanagh Breakdown of academic impact, for papers by Melanie Mackean Breakdown of academic impact, for papers by C. Sessa Breakdown of academic impact, for papers by Mariagrazia Distefano Breakdown of academic impact, for papers by Kaoru Niimi Breakdown of academic impact, for papers by Gianni Amunni Breakdown of academic impact, for papers by Jurjees Hasan Breakdown of academic impact, for papers by F. Raja Breakdown of academic impact, for papers by J. Carmichael
Rankless by CCL
2026